Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Depeng Li

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Haematologica|May 26, 2018
NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosisJianlin Qiao, Xiaoqing Wu, Qi Luo, et al.
Clinical and Experimental Medicine|September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myelomaRuixue Ma, Qi Zhang, Yang Liu, et al.
Nature Communications|April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trialMing Shi, Jiaojiao Wang, Hongming Huang, et al.
American Journal of Hematology|August 28, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapyYuekun Qi, Hujun Li, Kunming Qi, et al.
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trialDian Zhou, Qian Sun, Jieyun Xia, et al.
Blood|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary diseaseDian Zhou, Yuekun Qi, Sha Ma, et al.
Blood|March 26, 2022
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSLYuekun Qi, Mingfeng Zhao, Yongxian Hu, et al.
Blood Advances|September 29, 2021
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myelomaYing Wang, Chunrui Li, Jieyun Xia, et al.
Frontiers in Immunology|March 12, 2021
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell TreatmentZhiling Yan, Huanxin Zhang, Jiang Cao, et al.
Blood|March 16, 2025
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myelomaSha Ma, Jieyun Xia, Miao Zhang, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Haematologica|May 26, 2018
NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosisJianlin Qiao, Xiaoqing Wu, Qi Luo, et al.
Clinical and Experimental Medicine|September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myelomaRuixue Ma, Qi Zhang, Yang Liu, et al.
Nature Communications|April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trialMing Shi, Jiaojiao Wang, Hongming Huang, et al.
American Journal of Hematology|August 28, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapyYuekun Qi, Hujun Li, Kunming Qi, et al.
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trialDian Zhou, Qian Sun, Jieyun Xia, et al.
Blood|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary diseaseDian Zhou, Yuekun Qi, Sha Ma, et al.
Blood|March 26, 2022
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSLYuekun Qi, Mingfeng Zhao, Yongxian Hu, et al.
Blood Advances|September 29, 2021
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myelomaYing Wang, Chunrui Li, Jieyun Xia, et al.
Frontiers in Immunology|March 12, 2021
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell TreatmentZhiling Yan, Huanxin Zhang, Jiang Cao, et al.
Blood|March 16, 2025
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myelomaSha Ma, Jieyun Xia, Miao Zhang, et al.
Pageof 11